NCT04505137View on ClinicalTrials.gov

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

GMA301 Injection

GMA301 Injection administered as a single dose of 1500 mg

OTHER

GMA301 Placebo Injection

GMA301 Injection without GMA301 administered as a single intravenous dose

DRUG

GMA301 Injection

GMA301 Injection administered as a single dose of 2000 mg

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors

Collaborators (1)

Metaclinical
All Listed Sponsors
collaborator

Metaclinical

UNKNOWN

collaborator

Syneos Heath

UNKNOWN

lead

Gmax Biopharm Australia Pty Ltd.

INDUSTRY

NCT04505137 - A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers | Biotech Hunter | Biotech Hunter